Pentadecanoic acid (C15:0) is a saturated odd-chain fatty acid found naturally in full-fat dairy and ruminant fats. Until recently it attracted little scientific attention, largely lumped in with saturated fats as nutritionally unimportant. That began to change when researchers proposed that C15:0 plays an active role in cellular stability — integrating into cell membranes, modulating key metabolic receptors, and possibly helping to slow two well-studied drivers of cellular aging: ferroptosis and senescence.
The hypothesis that low C15:0 intake could constitute a newly recognized deficiency syndrome linked to accelerated aging is a significant and still-contested scientific claim. The evidence base is growing but remains early-stage, with most findings drawn from cell-based assays, animal models, and observational analyses rather than randomized human trials. This article summarizes what current research proposes, what it has demonstrated so far, and where important uncertainties remain.
Key Takeaways
- C15:0 is a naturally occurring odd-chain fatty acid proposed to stabilize cell membranes and act as a partial PPAR-α/δ agonist, influencing pathways relevant to inflammation, mitochondrial function, and fat oxidation.
- The ‘Cellular Stability Hypothesis’ proposes that low C15:0 intake accelerates aging via ferroptosis and cellular senescence, but this remains a working hypothesis not formally adopted by regulatory or mainstream nutrition bodies [2].
- Preclinical evidence shows C15:0 can modulate ferroptosis pathways in rat liver tissue [3], and cell assay data indicate biological activity profiles overlapping with established longevity compounds [1] — but human clinical trial data are lacking.
- Cross-species observations in dolphins link C15:0 levels to neurological aging markers [4], adding biological plausibility to the hypothesis without confirming human outcomes.
- C15:0 supplements appear well-tolerated at 100–300 mg/day in published research, but long-term human efficacy and safety data are not yet available, and the FDA has not evaluated C15:0 for any disease treatment or prevention.
What Is C15:0 and Why Might It Affect Aging?
C15:0 is a 15-carbon saturated fatty acid whose odd-chain structure sets it apart from more common even-chain fats like palmitic acid (C16:0). When metabolized, odd-chain fats yield a propionyl-CoA terminal fragment that feeds into the citric acid cycle via methylmalonyl-CoA and succinyl-CoA — a pathway distinct from standard even-chain fat oxidation. This metabolic route has implications for mitochondrial energy substrates and cellular biosynthesis.
Beyond metabolism, C15:0 has been proposed to act as a partial agonist of peroxisome proliferator-activated receptors alpha and delta (PPAR-α/δ), nuclear receptors that regulate fat oxidation, mitochondrial biogenesis, and inflammatory signaling. These are among the same pathways engaged by several compounds studied in longevity research. A 2023 cell-based analysis found that C15:0 shares statistically similar biological activities with leading longevity-enhancing compounds, including rapamycin and metformin [1]. This is a mechanistic observation from lab assays, not evidence of clinical equivalence, but it supports the rationale for deeper investigation.
The Cellular Stability Hypothesis: Framing C15:0 Deficiency and Aging
In 2024, Epitracker researchers formally articulated the ‘Cellular Stability Hypothesis,’ proposing that chronically low C15:0 intake may represent a previously unrecognized nutritional deficiency syndrome associated with ferroptosis and accelerated aging-related diseases [2]. The argument draws on population-level observations linking declining full-fat dairy consumption with rising rates of certain chronic conditions, alongside mechanistic data from cell and animal studies.
The hypothesis centers on two specific aging-associated cellular processes. First, ferroptosis — a form of iron-dependent regulated cell death triggered by lipid peroxidation in cell membranes. Second, cellular senescence — the accumulation of dysfunctional cells that resist normal cell death and release inflammatory signals that impair tissue repair. The researchers propose that adequate C15:0 in cell membranes may buffer against both processes [2]. This framing has not been formally adopted by regulatory bodies or mainstream nutrition science organizations, and confirmation in rigorous human clinical trials is still needed.
Ferroptosis: Iron-Dependent Cell Death and C15:0's Proposed Protective Role
Ferroptosis is distinct from apoptosis and necrosis. It is driven by the iron-catalyzed oxidation of polyunsaturated fatty acids embedded in cell membranes, generating toxic lipid peroxides that disrupt membrane integrity. Because the fatty acid composition of membranes directly determines their susceptibility to this process, dietary fatty acid intake is mechanistically relevant to ferroptotic risk.
A 2025 rat study examined whether C15:0 could protect against ferroptosis in a thioacetamide-induced liver fibrosis model. The study found that C15:0 attenuated liver fibrosis by modulating oxidative stress, inflammation, and ferroptosis pathways [3]. This is a preclinical result in a disease-state animal model rather than healthy aging tissue, but it provides direct mechanistic evidence that C15:0 can influence ferroptosis-related biology in living organisms. No human clinical trials replicating these protective effects have been published to date.
Cellular Senescence and the Chronic Inflammation of Aging
Senescent cells are cells that have permanently exited the cell cycle but resist programmed death. As they accumulate with age, they secrete a cocktail of inflammatory cytokines, matrix-degrading proteases, and growth factors collectively termed the senescence-associated secretory phenotype (SASP). This sustained low-grade inflammation — sometimes called ‘inflammaging’ — is associated with tissue dysfunction across multiple organ systems and is an active target of longevity research.
The 2023 cell-based analysis that compared C15:0 to known longevity compounds found that C15:0 demonstrated activity profiles consistent with reducing cellular senescence markers in vitro, alongside anti-inflammatory and mitochondrial-protective effects [1]. These were assay results, not outcomes in living organisms, and C15:0 should not be equated with approved senolytic therapies based on this evidence alone. Still, the breadth of the activity profile observed in cell assays supports continued investigation into whether these effects translate to human aging contexts.
Neurological Aging: Cross-Species Observations from Dolphins
Bottlenose dolphins are long-lived mammals with diets naturally rich in odd-chain fatty acids from fish, making them an informative comparative model for aging research. A 2025 study examining aging-associated amyloid-β plaques and neuroinflammation in dolphins also explored the potential cognitive health-supporting roles of pentadecanoic acid [4]. The study observed correlations between C15:0 levels and aging-associated neurological markers, suggesting a possible role for dietary C15:0 in supporting brain health during aging.
Cross-species observations of this kind are hypothesis-generating rather than clinically conclusive for humans. Dolphins share meaningful metabolic and neurological characteristics with humans, lending the findings scientific interest, but species-specific physiology, dietary context, and the observational study design all limit direct extrapolation. Human clinical trials examining C15:0 and cognitive aging outcomes have not yet been conducted.
Metabolic Nuances: How Odd-Chain Fatty Acid Intake Is Processed
C15:0’s proposed benefits depend in part on how the body processes odd-chain fatty acids at higher intake levels. Supplementation introduces meaningfully more of this compound than most modern diets provide, particularly in populations that have moved toward low-fat dairy products. A 2025 mouse study feeding odd-chain dicarboxylic acids found they produced a metabolic signature resembling glutaric aciduria type 1 — an unexpected result suggesting that concentrated odd-chain fatty acid intake can create downstream metabolic effects not fully anticipated from baseline dietary exposure [5].
This finding specifically concerns odd-chain dicarboxylic acids rather than C15:0 itself, and its clinical relevance to human C15:0 supplementation at studied doses (100–300 mg/day) is not established. However, it underscores that odd-chain fatty acid metabolism is not completely characterized, and that the full consequences of substantially increasing intake — especially over the long term — warrant further study. Published C15:0 supplementation trials have reported no serious adverse events at these doses, but long-term human safety data remain limited.
🛒 Where to Buy Pentadecanoic Acid (C15:0)
- Epitracker Fatty15 C15:0 Fatty Acid SupplementLab-tested / studied
capsules, 100 mg C15:0 per capsule; 1 capsule/day starter, 2 capsules/day maintenance — Category creator; the only C15:0 supplement backed by the original Epitracker research team (Venn-Watson et al.); uses a patented, sustainably-sourced pure C15:0 ingredient; most expensive per-capsule but reference product for all comparisons - Double Wood Supplements Pentadecanoic Acid C15:0
capsules, 200 mg C15:0 per serving (2 capsules) — One of the first genericized C15:0 supplements; significantly lower price than Fatty15; no independent clinical trials on this specific product; good option for budget-conscious buyers who want to trial the fatty acid - Sports Research Pentadecanoic Acid C15:0
softgels, 100 mg C15:0 per softgel — Established supplement brand with strong Amazon presence; third-party tested; softgel form may aid fat-soluble absorption; competitively priced mid-tier option - BulkSupplements Pentadecanoic Acid Powder (C15:0)
powder, 100–300 mg per measured serving — Most economical option for higher-dose protocols or stackers; requires a milligram-accurate scale; no excipients or additives; not recommended for beginners unfamiliar with powder dosing
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The evidence for C15:0’s role in ferroptosis prevention, senescence reduction, and longevity is scientifically interesting but predominantly preclinical — most findings come from cell assays, animal models, and observational correlations rather than human clinical trials, and the FDA has not evaluated C15:0 for treating or preventing any disease. Individuals with metabolic disorders, liver conditions, or those taking medications that affect lipid metabolism should consult a qualified healthcare provider before using C15:0 supplements.
Frequently Asked Questions
What is ferroptosis and how is C15:0 proposed to prevent it?
Ferroptosis is a form of regulated cell death triggered by iron-dependent oxidation of fatty acids in cell membranes, generating lipid peroxides that destroy membrane integrity. C15:0 is proposed to integrate into membranes and reduce their vulnerability to this oxidative process. A 2025 rat study found C15:0 attenuated fibrosis by modulating ferroptosis pathways in liver tissue [3], though this is preclinical evidence and not confirmed in human studies.
Is the claim that C15:0 is an 'essential' fatty acid scientifically accepted?
Not yet by mainstream bodies. The proposal that C15:0 is an essential fatty acid whose deficiency constitutes a newly identified syndrome linked to aging-associated disease is a hypothesis advanced by Epitracker researchers [2]. It has not been formally adopted by the FDA, EFSA, or major nutrition science organizations. Confirmation requires randomized controlled human trials that have not yet been published.
How does C15:0's longevity activity profile compare to rapamycin or metformin?
A 2023 cell-based analysis found that C15:0 shares statistically similar biological activities with rapamycin, metformin, and other longevity-associated compounds across a panel of cell assays [1]. This is mechanistic overlap observed in lab conditions, not evidence of clinical equivalence or comparable efficacy. C15:0 has not been tested head-to-head against these compounds in animal models or human trials.
What do the dolphin studies contribute to understanding C15:0 and brain aging?
Bottlenose dolphins are long-lived mammals with naturally high odd-chain fatty acid intake. A 2025 study found correlations between C15:0 levels and aging-associated neurological changes in dolphins, including amyloid-β plaques and neuroinflammation markers, and explored C15:0’s potential cognitive health-supporting roles [4]. These cross-species observations add biological plausibility to the hypothesis but cannot be directly extrapolated to human clinical outcomes.
Are there any known risks or metabolic concerns with C15:0 supplementation?
Published studies at 100–300 mg/day have reported no serious adverse events. However, a 2025 mouse study on odd-chain dicarboxylic acid feeding found an unexpected metabolic signature resembling a rare metabolic disorder [5], indicating that odd-chain fatty acid metabolism at higher doses is not fully characterized. Long-term human safety data are limited, and individuals with metabolic or liver conditions should consult a physician before supplementing.
What are the main dietary sources of C15:0?
C15:0 is found primarily in full-fat dairy products — butter, whole milk, aged cheese — and in ruminant animal fats. Dietary intake has declined in populations that have shifted to low-fat dairy, which forms part of the basis for the deficiency hypothesis [2]. Some fatty fish also contribute minor amounts of odd-chain fatty acids. Concentrated C15:0 supplements derived from sustainably sourced algae or dairy lipid fractions are also commercially available.
References
- Venn-Watson S et al. Pentadecanoic Acid (C15:0), an Essential Fatty Acid, Shares Clinically Relevant Cell-Based Activities with Leading Longevity-Enhancing Compounds. Nutrients (2023). PMID 37960259
- Venn-Watson S et al. The Cellular Stability Hypothesis: Evidence of Ferroptosis and Accelerated Aging-Associated Diseases as Newly Identified Nutritional Pentadecanoic Acid (C15:0) Deficiency Syndrome. Metabolites (2024). PMID 39057678
- Aabis M et al. Pentadecanoic acid attenuates thioacetamide-induced liver fibrosis by modulating oxidative stress, inflammation, and ferroptosis pathways in rat. Naunyn-Schmiedeberg's archives of pharmacology (2025). PMID 40310526
- Venn-Watson S et al. Aging-Associated Amyloid-β Plaques and Neuroinflammation in Bottlenose Dolphins (Tursiops truncatus) and Novel Cognitive Health-Supporting Roles of Pentadecanoic Acid (C15:0). International journal of molecular sciences (2025). PMID 40332352
- Richert AC et al. Odd-Chain Dicarboxylic Acid Feeding Produces a Glutaric Aciduria Type 1-Like Metabolic Signature in Mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2025). PMID 41196119
